



1- LVEF drop was not different in the two groups. (-1.59 ± 2.67 vs. -2.09 ± 1.75 , melatonin and placebo, respectively)

2- The decrease in the GLS was significantly lower in the melatonin group than in the placebo group. (-0.75 ± 3.22 vs. -3.68 ± 3.06 respectively)

3- The average increase in CTnI in the melatonin group was significantly lower than in the placebo group.

A triple-blinded, randomized, placebo-controlled trial to assess melatonin effect in the prevention of doxorubicin-induced cardiotoxicity in non-metastatic breast cancer receiving doxorubicin plus cyclophosphamide